Report Highlights

India Medical Device Connectivity: Market Overview

The medical device connectivity market in India is valued at USD 1.42 billion in 2024 and is structured around three distinct demand pools: large private hospital chains investing in enterprise-grade clinical integration engines, public health facilities receiving connectivity infrastructure through government-funded digital health missions, and the rapidly expanding home healthcare segment driven by post-COVID chronic disease management. The market's current architecture reflects a decade of fragmented procurement, where device acquisition was prioritised over interoperability, leaving a legacy integration challenge that is now the primary growth driver for middleware and connectivity platform vendors operating in the country.

Government policy has been the dominant shaping force in this market. The National Digital Health Mission, rebranded as the Ayushman Bharat Digital Mission (ABDM) and operationalised through the National Health Authority (NHA), established the foundational data exchange architecture that now governs how medical devices must communicate within funded facilities. Private sector actors, particularly Tier 1 hospital chains in metro centres, have moved faster than the regulatory framework in deploying integrated connectivity systems, creating a bifurcated market where standards compliance and technical capability do not yet fully overlap. The gap between these two segments defines the medium-term competitive landscape.

Policy-Driven Growth in India's Medical Device Connectivity Market

Three specific policy mechanisms are directly translating into market demand for connectivity solutions. First, the ABDM Health Data Management Policy, notified in 2022, mandates that all NHA-participating facilities adopt the Unified Health Interface (UHI) and Health Information Exchange and Consent Manager (HI-EM) frameworks. Facilities processing claims under the Pradhan Mantri Jan Arogya Yojana (PM-JAY) scheme, which covers over 500 million beneficiaries, are required to demonstrate digital health record generation linked to ABHA identifiers, creating a direct, compliance-driven procurement pipeline for connectivity hardware and integration software estimated at USD 180 million annually across empanelled institutions.

Second, the Ministry of Electronics and Information Technology (MeitY) Medical Electronics Policy 2022 allocated INR 4,000 crore in production-linked incentives for domestic medical electronics manufacturing, a portion of which targets connected device production. Third, the Central Government Health Scheme (CGHS) revised its 2023 empanelment criteria to require digital discharge summaries and device-linked diagnostic data from all empanelled hospitals, effectively making connectivity capability a prerequisite for accessing the CGHS beneficiary base of approximately 4.5 million covered individuals. Each of these mechanisms creates mandatory, time-bound demand that vendors can directly contract against, distinguishing this market from discretionary enterprise IT spending cycles.

Regulatory Barriers and Compliance Costs

The primary regulatory barrier is the Medical Devices Rules, 2017 (amended 2020), administered by the Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health and Family Welfare. CDSCO's device registration process for Class B and Class C connected medical devices requires clinical performance data, electromagnetic compatibility certification, and cybersecurity documentation aligned with IEC 80001-1 standards. Average approval timelines for imported connected devices currently run between 9 and 18 months, creating significant market entry delays for foreign OEMs. CDSCO's online SUGAM portal has reduced paperwork friction but has not meaningfully shortened substantive technical review periods, which remain a competitive disadvantage relative to Singapore's HSA, where comparable approvals take 4 to 6 months.

A second barrier is the Bureau of Indian Standards (BIS) compulsory registration requirement under the Electronics and Information Technology Goods (Requirement for Compulsory Registration) Order, which applies to Wi-Fi-enabled and Bluetooth-connected medical peripherals. BIS registration requires laboratory testing at BIS-recognised facilities, adding INR 3–8 lakh per device category in direct compliance costs, plus 60–90 days of additional timeline. Local content requirements embedded in government procurement rules under the Public Procurement (Preference to Make in India) Order, 2017 further restrict foreign-manufactured connectivity equipment from direct government tender participation unless a domestic value-addition threshold of 50% is demonstrated, effectively pushing international vendors into joint venture or local manufacturing arrangements that carry their own structural costs.

Policy-Created Opportunities in India

The most commercially significant near-term opportunity is the NHA's ABDM Phase 3 rollout, which is expected to extend interoperability mandates to Tier 2 and Tier 3 cities through state-level Health System Strengthening grants under the National Health Mission (NHM). States including Andhra Pradesh, Rajasthan, and Himachal Pradesh have already published expression-of-interest documents for district hospital connectivity infrastructure under NHM's Health and Wellness Centre digitisation programme. This creates a procurement pipeline spanning over 1,500 facilities, requiring device gateways, middleware integration engines, and cloud-based data aggregation platforms, with state governments covering 60% of capital expenditure through NHM funding transfers from the Centre.

A second opportunity is embedded in the Indian Council of Medical Research (ICMR) and Department of Biotechnology's joint AI in Health initiative, which requires real-time device data streams to train and validate clinical AI models under the National AI Strategy. Vendors offering connectivity platforms with standardised API outputs compatible with ICMR's data commons infrastructure are positioned to secure long-term data services contracts outside standard procurement cycles. Additionally, the 2023 amendment to the Insurance Regulatory and Development Authority of India (IRDAI) health insurance regulations, requiring cashless settlement within 3 hours at network hospitals, is accelerating private hospital investment in real-time device connectivity to support automated claims documentation, creating a private-pay demand segment entirely independent of government funding.

Market at a Glance

Leading Market Participants

• Philips India Limited
• Siemens Healthineers India
• GE HealthCare India
• Wipro GE Healthcare
• Honeywell Life Care Solutions India
• HCL Technologies (Health Practice)
• Tata Consultancy Services (Healthcare Division)
• Medtronic India
• Dräger India
• Nihon Kohden India

Regulatory and Policy Environment

The primary legislative instrument governing medical device connectivity in India is the Medical Devices Rules, 2017, issued under the Drugs and Cosmetics Act, 1940, and administered by CDSCO. The Rules classify connected medical devices by risk category, with Class B devices requiring state licensing authority approval and Class C and D devices requiring CDSCO central approval. Overlaid on this is the Digital Information Security in Healthcare Act (DISHA), which, though not yet enacted as of 2025, has a draft framework that will impose strict data localisation requirements on health device data, requiring all patient-linked device outputs to be stored on servers within Indian territory. The NHA's Unified Health Interface technical specifications, updated in February 2024, now mandate HL7 FHIR R4 compliance for all devices integrated into ABDM-participating networks, setting a de facto interoperability standard that precedes formal statutory codification.

Compared to regional peers, India's regulatory framework is more complex than Thailand's FDA medical device pathway but less mature than China's NMPA, which has already implemented binding AI medical device cybersecurity standards. India's CDSCO has published draft guidance on Software as a Medical Device (SaMD), aligning partially with IMDRF guidelines, with final rules expected by Q3 2026. The upcoming Personal Data Protection Act, 2023 (Digital Personal Data Protection Act), which received Presidential assent in August 2023, introduces consent-based data processing obligations that directly affect how connectivity platforms handle biometric and health data, with full enforcement expected from the Data Protection Board of India by mid-2026. Vendors must plan product architectures around these forthcoming obligations immediately to avoid costly redesigns at enforcement onset.

Long-Term Policy Outlook for India's Medical Device Connectivity Market

By 2032, three policy shifts are expected to fundamentally reshape the market structure. The enactment and enforcement of DISHA will create a mandatory data sovereignty layer, requiring all connectivity platform providers to deploy India-specific cloud infrastructure rather than routing health device data through global nodes. This will advantage domestic cloud providers such as Jio Cloud and NIC's MeghRaj platform while increasing compliance costs for multinational vendors relying on AWS or Azure global regions. Simultaneously, the NITI Aayog's National Data and Analytics Platform is expected to integrate with ABDM, creating a national device data repository that will unlock federated analytics contracts for connectivity vendors offering standardised data pipeline services to central and state governments.

The second major shift is the expected extension of the Production Linked Incentive (PLI) Scheme for medical devices beyond its current 2027 sunset, with a proposed second tranche specifically targeting IoT-enabled and AI-integrated connected devices as identified in the National Medical Devices Policy 2023. This will incentivise domestic manufacturing of device gateways and connectivity modules, progressively reducing import dependence and altering the competitive dynamics that currently favour multinational hardware OEMs. Vendors who establish domestic manufacturing or deep localisation partnerships before the second PLI tranche is notified will lock in cost advantages that latecomers cannot replicate within a five-year horizon. The policy trajectory unambiguously favours early-mover domestic manufacturing commitment over import-led distribution strategies.

Market Segmentation

By Component

• Hardware (Device Gateways, Hubs, Routers)
• Software (Integration Engines, Middleware Platforms)
• Services (Implementation, Managed Services, Support)
• Cloud-Based Platforms
• On-Premise Solutions

By Connectivity Technology

• Wired Connectivity (Ethernet, USB)
• Wireless Connectivity (Wi-Fi, Bluetooth, Zigbee)
• Cellular and 5G Networks
• RFID and NFC
• Proprietary Protocols

By End User

• Hospitals and Clinics
• Diagnostic and Imaging Centres
• Home Healthcare Providers
• Ambulatory Surgical Centres
• Government Health Facilities

By Application

• Patient Monitoring
• Electronic Health Records Integration
• Medical Imaging and Diagnostics
• Medication Management
• Telehealth and Remote Monitoring
• Asset and Inventory Tracking

Frequently Asked Questions

Q1. What regulatory approval does a connected medical device require before it can be sold in India? ▼

All connected medical devices must be registered with CDSCO under the Medical Devices Rules, 2017, with the risk classification determining whether state or central approval is needed. Additionally, Wi-Fi and Bluetooth-enabled devices require BIS compulsory registration under the IT Goods Registration Order before commercial sale.

Q2. How does ABDM compliance affect procurement eligibility for hospital connectivity vendors? ▼

Vendors supplying connectivity solutions to PM-JAY empanelled hospitals must demonstrate compatibility with the NHA's Unified Health Interface and HL7 FHIR R4 standards as updated in February 2024. Non-compliant platforms are excluded from government procurement tenders and NHM Health System Strengthening grants, which represent the largest public-sector spending pool in this market.

Q3. What does the Digital Personal Data Protection Act, 2023 require from medical device connectivity platforms? ▼

The Act requires platforms handling patient health data to obtain explicit consent before processing, maintain data fiduciary obligations, and report breaches to the Data Protection Board of India within prescribed timelines. Full enforcement is expected by mid-2026, and platforms must redesign data pipeline architectures to include consent management modules before that date.

Q4. How does the Make in India local content requirement affect foreign connectivity hardware vendors? ▼

Under the Public Procurement (Preference to Make in India) Order, 2017, foreign-manufactured connectivity hardware must demonstrate 50% domestic value addition to qualify for direct government tender participation. Vendors unable to meet this threshold must partner with Indian manufacturers or distributors, or accept exclusion from the public-sector procurement pipeline entirely.

Q5. What is the expected impact of the DISHA enactment on cloud infrastructure for connectivity platforms? ▼

DISHA's data localisation provisions will require all patient-linked device data generated in India to be stored on India-domiciled servers, effectively prohibiting routing through global cloud regions. Vendors currently using international cloud nodes must migrate to domestic infrastructure providers before DISHA enforcement begins, estimated to require 18 to 24 months of architectural transition work.